Seres Therapeutics (NASDAQ:MCRB) Upgraded at StockNews.com

StockNews.com upgraded shares of Seres Therapeutics (NASDAQ:MCRB) from a sell rating to a hold rating in a research report report published on Friday morning.

Several other equities research analysts have also weighed in on the company. Canaccord Genuity Group restated a “buy” rating and issued a $10.00 target price on shares of Seres Therapeutics in a report on Thursday, November 14th. JPMorgan Chase & Co. downgraded Seres Therapeutics from a “neutral” rating to an “underweight” rating in a research report on Thursday, October 24th. Finally, Chardan Capital reaffirmed a “buy” rating and issued a $1.25 price target on shares of Seres Therapeutics in a research report on Wednesday, November 13th. One research analyst has rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat.com, Seres Therapeutics currently has a consensus rating of “Hold” and a consensus target price of $5.08.

Seres Therapeutics Stock Performance

MCRB opened at $0.91 on Friday. The business has a 50 day moving average price of $0.82 and a 200 day moving average price of $0.90. Seres Therapeutics has a twelve month low of $0.54 and a twelve month high of $2.05. The firm has a market cap of $154.59 million, a P/E ratio of -3.94 and a beta of 2.13.

Institutional Trading of Seres Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the company. Virtu Financial LLC boosted its stake in Seres Therapeutics by 44.8% in the 3rd quarter. Virtu Financial LLC now owns 58,791 shares of the biotechnology company’s stock valued at $56,000 after buying an additional 18,191 shares in the last quarter. Providence Wealth Advisors LLC boosted its stake in Seres Therapeutics by 49.5% in the second quarter. Providence Wealth Advisors LLC now owns 76,250 shares of the biotechnology company’s stock worth $58,000 after purchasing an additional 25,250 shares in the last quarter. Point72 DIFC Ltd acquired a new position in Seres Therapeutics in the second quarter worth $64,000. Point72 Asia Singapore Pte. Ltd. acquired a new position in Seres Therapeutics in the second quarter worth $92,000. Finally, State Street Corp boosted its stake in Seres Therapeutics by 12.9% in the third quarter. State Street Corp now owns 383,248 shares of the biotechnology company’s stock worth $363,000 after purchasing an additional 43,700 shares in the last quarter. 59.34% of the stock is currently owned by institutional investors.

About Seres Therapeutics

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.